WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H328055
CAS#: 147362-57-0
Description: Loviride, also known as R-89439, is a RNA-directed DNA polymerase inhibitor potentially for the treatment of HIV infection.
Hodoodo Cat#: H328055
Name: Loviride
CAS#: 147362-57-0
Chemical Formula: C17H16Cl2N2O2
Exact Mass: 350.06
Molecular Weight: 351.227
Elemental Analysis: C, 58.14; H, 4.59; Cl, 20.19; N, 7.98; O, 9.11
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Loviride; R-89439; R 89439; R89439; R 089439; R089439.
IUPAC/Chemical Name: 2-((2-acetyl-5-methylphenyl)amino)-2-(2,6-dichlorophenyl)acetamide
InChi Key: CJPLEFFCVDQQFZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23)
SMILES Code: O=C(N)C(NC1=CC(C)=CC=C1C(C)=O)C2=C(Cl)C=CC=C2Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 351.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Bevernage J, Brouwers J, Annaert P, Augustijns P. Drug precipitation-permeation interplay: supersaturation in an absorptive environment. Eur J Pharm Biopharm. 2012 Oct;82(2):424-8. doi: 10.1016/j.ejpb.2012.07.009. PubMed PMID: 22841881.
2: Bevernage J, Hens B, Brouwers J, Tack J, Annaert P, Augustijns P. Supersaturation in human gastric fluids. Eur J Pharm Biopharm. 2012 May;81(1):184-9. doi: 10.1016/j.ejpb.2012.01.017. PubMed PMID: 22342777.
3: Bevernage J, Forier T, Brouwers J, Tack J, Annaert P, Augustijns P. Excipient-mediated supersaturation stabilization in human intestinal fluids. Mol Pharm. 2011 Apr 4;8(2):564-70. doi: 10.1021/mp100377m. PubMed PMID: 21268663.
4: Bevernage J, Brouwers J, Clarysse S, Vertzoni M, Tack J, Annaert P, Augustijns P. Drug supersaturation in simulated and human intestinal fluids representing different nutritional states. J Pharm Sci. 2010 Nov;99(11):4525-34. doi: 10.1002/jps.22154. PubMed PMID: 20845451.
5: Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Humbeeck JV, Van den Mooter G, Augustijns P. Solubility increases associated with crystalline drug nanoparticles: methodologies and significance. Mol Pharm. 2010 Oct 4;7(5):1858-70. doi: 10.1021/mp100209b. PubMed PMID: 20822111.
6: Van Eerdenbrugh B, Stuyven B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. Downscaling drug nanosuspension production: processing aspects and physicochemical characterization. AAPS PharmSciTech. 2009;10(1):44-53. doi: 10.1208/s12249-008-9170-5. PubMed PMID: 19148764; PubMed Central PMCID: PMC2663663.
7: Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci. 2008 Sep 2;35(1-2):127-35. doi: 10.1016/j.ejps.2008.06.009. PubMed PMID: 18644441.
8: Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, Van den Mooter G. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm. 2007 Jun 29;338(1-2):198-206. PubMed PMID: 17363200.
9: Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial). Antivir Ther. 2002 Mar;7(1):11-20. PubMed PMID: 12008783.
10: Ludovici DW, Kukla MJ, Grous PG, Krishnan S, Andries K, de Béthune MP, Azijn H, Pauwels R, De Clercq E, Arnold E, Janssen PA. Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). Bioorg Med Chem Lett. 2001 Sep 3;11(17):2225-8. PubMed PMID: 11527703.
11: Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, Janssen PA, Kleim JP, Rösner M, Hughes SH, Arnold E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol. 2001 Jun 1;309(2):437-45. PubMed PMID: 11371163.
12: Murphy RL. Nonnucleoside reverse transcriptase inhibitors. AIDS Clin Care. 1997 Oct;9(10):75-7, 79. PubMed PMID: 11364757.
13: Clarke JR, Kaye S, Babiker AG, Hooker MH, Tedder R, Weber JN. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues. J Virol Methods. 2000 Aug;88(2):117-24. PubMed PMID: 10960699.
14: Witvrouw M, Pannecouque C, Desmyter J, De Clercq E, Andries K. In vitro evaluation of the effect of temporary removal of HIV drug pressure. Antiviral Res. 2000 Jun;46(3):215-21. PubMed PMID: 10867159.
15: Gatell J, Lange J, Gartland M. AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group. Antivir Ther. 1999;4(2):79-86. PubMed PMID: 10682152.
16: A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection--the Quattro Trial. Quattro Steering Committee. AIDS. 1999 Nov 12;13(16):2209-17. PubMed PMID: 10563706.
17: Chatterton ML, Scott-Lennox J, Wu AW, Scott J. Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection. Pharmacoeconomics. 1999;15 Suppl 1:67-74. PubMed PMID: 10537443.
18: Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS. 1999 Aug 20;13(12):1477-83. PubMed PMID: 10465070.
19: Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 1999 Sep;180(3):607-13. PubMed PMID: 10438346.
20: De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco. 1999 Jan-Feb;54(1-2):26-45. Review. PubMed PMID: 10321027.
